NCT06169072View on ClinicalTrials.gov

Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2027

Conditions
Breast CancerSentinel Lymph Node
Interventions
DRUG

Superparamagnetic Iron Oxide

Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension. In this study injected intradermally in an ultra-low dose

DEVICE

Technetium99

Technetium99 +/- blue dye is injected per routine as a comparator and as back up.

Trial Locations (1)

41345

RECRUITING

Sahlgrenska Iniversity Hospital, Gothenburg

All Listed Sponsors
lead

Vastra Gotaland Region

OTHER_GOV